enGene Holdings Inc. (NASDAQ:ENGN) Major Shareholder De Solidarite Des Travai Fonds Sells 47,854 Shares of Stock

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of the company’s stock in a transaction on Monday, April 22nd. The shares were sold at an average price of $15.00, for a total transaction of $717,810.00. Following the completion of the sale, the insider now directly owns 3,036,153 shares in the company, valued at $45,542,295. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

De Solidarite Des Travai Fonds also recently made the following trade(s):

• On Thursday, April 18th, De Solidarite Des Travai Fonds sold 4,575 shares of enGene stock. The shares were sold at an average price of $15.01, for a total transaction of $68,670.75.

enGene Trading Down 0.3 %

Shares of ENGN opened at $14.80 on Tuesday. The stock has a fifty day moving average price of $16.11. enGene Holdings Inc. has a 12-month low of $6.69 and a 12-month high of $43.00.

Analyst Ratings Changes

A number of research analysts have recently issued reports on ENGN shares. Morgan Stanley initiated coverage on enGene in a research note on Friday, March 8th. They issued an “overweight” rating and a $40.00 price objective on the stock. Wells Fargo & Company initiated coverage on enGene in a report on Monday. They set an “overweight” rating and a $30.00 price target on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of enGene in a research note on Tuesday, February 20th. UBS Group began coverage on shares of enGene in a research note on Thursday, March 28th. They set a “buy” rating and a $37.00 target price on the stock. Finally, SVB Leerink assumed coverage on shares of enGene in a research note on Tuesday, February 20th. They issued an “outperform” rating and a $31.00 price target for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $34.40.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Vivo Capital LLC bought a new stake in shares of enGene during the fourth quarter worth about $6,264,000. Omega Fund Management LLC bought a new stake in enGene during the 4th quarter worth approximately $10,441,000. BVF Inc. IL purchased a new stake in shares of enGene in the fourth quarter worth approximately $20,777,000. Finally, Fcpm Iii Services B.V. bought a new position in shares of enGene in the fourth quarter valued at approximately $80,097,000. 64.16% of the stock is owned by institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.